Good news: Merck to add 310 jobs; bad news: Biovail/Valeant to cut 1,100

It promised North Carolina 440 jobs in two years to meet increased demand for its vaccines. Merck now says it will add 310 more. "We have grown much faster than anyone had anticipated," says plant manager John Wagner. Separately, the drug giant says it is delaying the closure of some Dutch operations while it sorts out alternatives for employees.  Both the U.S. and Canada will suffer job losses thanks to synergies identified in the Biovail acquisition of Valeant. The combined 4,400-employee workforce is expected to be trimmed by 25 percent. Report | Article | Article

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.